Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents-Reference-Cited by-同舟云学术

Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents

Published:2016-02 Issue: Volume:41 Page:43-47
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Nazha Aziz^ORCID,Sekeres Mikkael A.,Garcia-Manero Guillermo,Barnard John,Al Ali Najla H.,Roboz Gail J.,Steensma David P.,DeZern Amy E.,Zimmerman Cassie,Jabbour Elias J.,Zell Katrina,List Alan F.,Kantarjian Hagop M.,Maciejewski Jaroslaw P.,Komrokji Rami S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference12 articles.

1. How we treat higher-risk myelodysplastic syndromes;Sekeres;Blood,2014

2. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management;Garcia-Manero;Am. J. Hematol.,2014

3. Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges;Bejar;American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting 2013,2013

4. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B;Silverman;J. Clin. Oncol.,2002

5. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study;Kantarjian;Cancer,2006

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen;Clinical Epigenetics;2023-10-26

2. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms;The Cancer Journal;2023-05

3. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes;The Cancer Journal;2023-05

4. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes;Blood;2023-02-01

5. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial;Blood;2023-01-12